New database lets marketers make house calls to docs

Share this article:

Healthcare Data Solutions (HDS) launched a new database providing home addresses and personal email account listings for physicians, dentists, nurses and other healthcare providers.

The database, called PrescriberPRO@Home, includes 190,000 home email addresses that are CAN-SPAM compliant, and half a million postal addresses that have been validated by the USPS, according to a statement.

Chris Lundgren, VP of sales at HDS, said product development at the company is driven by customer requests, adding that healthcare recruiters and publications in particular have expressed a need for home addresses and personal email lists.

The new database also helps HDS keep their physicians' office data — the company's "bread and butter," according to Lundgren — current, since doctors aren't likely to file a national change of address when they switch practices or move to a new office, but they would if their home address changed.

Lundgren said personal email address are often captured when doctors sign up to attend events or receive services, and many of HDS's clients already have the information.  "We clean up and enhance our clients' customer files for them," Lundgren said, adding that many customer files HDS receives for sprucing already contain personal email accounts and home addresses.

The PrescriberPRO@Home database allows marketers to sort results based on practice name, group or hospital affiliation, license information, specialty and other categories, the statement said.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.